Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
There are six weeks or less for medtech companies to be ready to operate as well as they can under Brexit – assuming that it will take place at the third time of asking. The new NHS procurement scheme, already in place, is another potentially disruptive concept for UK companies to adapt to.
A new digital ecosphere to support the efficient delivery of individualized cancer therapies to patients has been released by data and information management company EY. It is an open source framework that can be accessed by all stakeholders in the care delivery chain.
The UK continues to build its digital health care infrastructure, as seen in the recent funding pledge for a new AI Lab. Andrew Davies is the newly appointed digital health lead at the UK’s ABHI medtech industry association. He says stakeholders first need to understand the scope of digital health care, and then adopt a networked approach, with medtech playing a full part in that evolution.
Less than 2% of NHS England’s budget is spent on digital technology, compared with 4-5% in other industries, NHS chief information officer Dr. Simon Eccles told delegates at the NHS Health and Care Innovation Expo 2019 this week. But the new NHS AI Lab is seen as a big step in the right direction.
Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.
German Industry Says MDR Implementation 'Too Slow' But Negative Economic Effects Still Largely Unreported
The European Commission needs to be faster and more efficient in its implementation of the new EU Medical Device Regulation (MDR), say German manufacturers, watching the remaining months of transition time slip into single figures. A few economic operators have come clean about the pressure the MDR has brought to bear, but the suspicion is that many are choosing to keep quiet.